Global Peptide Therapeutics Market & Clinical Trials Insight 2022 report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market.
In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.
Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians.
But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.